CompletedPhase 2NCT02511132
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Studying Extraskeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gradalis, Inc.
- Principal Investigator
- John Nemunaitis, MDGradalis, Inc.
- Intervention
- Vigil(biological)
- Enrollment
- 22 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2016 – 2020
Study locations (6)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Nicklaus Children's Hospital (Miami Children's Health System), Miami, Florida, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cleveland Clinic Children's, Cleveland, Ohio, United States
- Mary Crowley Cancer Research Centers, Dallas, Texas, United States
- TOPA - Medical City Dallas Pediatric Hematology-Oncology, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02511132 on ClinicalTrials.gov